| Autor: |
Pierce KK, Whitehead SS, Diehl SA, Naro G, Carmolli MC, He H, Tibery CM, Sabundayo BP, Kirkpatrick BD, Durbin AP |
| Jazyk: |
angličtina |
| Zdroj: |
MedRxiv : the preprint server for health sciences [medRxiv] 2024 Jan 26. Date of Electronic Publication: 2024 Jan 26. |
| DOI: |
10.1101/2023.06.07.23291100 |
| Abstrakt: |
All four serotypes of dengue virus (DENV) cause the full spectrum of disease. Therefore, vaccines must protect against all serotypes. To evaluate candidate vaccines, a human challenge model of dengue serotype 3 (rDEN30Δ30) was developed. All challenge virus recipients safely met the primary endpoint of viremia and secondary endpoints of rash and seroconversion to DENV-3. |
| Databáze: |
MEDLINE |
| Externí odkaz: |
|
